He Chen-Xia, Shi Ding, Wu Wen-Jun, Ding You-Fa, Feng Deng-Min, Lu Bin, Chen Hao-Ming, Yao Ji-Hua, Shen Qi, Lu Da-Ru, Xue Jing-Lun
State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200433, China.
World J Gastroenterol. 2004 Feb 15;10(4):567-72. doi: 10.3748/wjg.v10.i4.567.
Transfer and expression of insulin gene in vivo are an alternative strategy to improve glycemic control in type 1 diabetes. Hydrodynamics-based procedure has been proved to be very efficient to transfer naked DNA to mouse livers. The basal hepatic insulin production mediated by this rapid tail vein injection was studied to determine its effect on the resumption of glycemic control in type 1 diabetic mice.
Engineered insulin cDNA was inserted into plasmid vectors under a CMV promoter, and transferred into STZ induced diabetic mice by hydrodynamic procedure. Glucose levels, body weight of treated mice, insulin levels, immunohistology of the liver, and quantity of insulin mRNA in the liver were assayed to identify the improvement of hyperglycemic complication after plasmid administration. Sleeping Beauty, a transposon system, was also used to prolong the insulin expression in the liver.
After plasmid administration, Plasma insulin was significantly increased in the diabetic mice and the livers were insulin-positive by immunostaining. At the same time the hyperglycemic complication was improved. The blood glucose levels of mice were reduced to normal. Glucose tolerance of the treated diabetic mice was improved. Body weight loss was also ameliorated. The rapid tail vein injection did not cause any fatal result.
Our results suggested that insulin gene could be efficiently transferred into the livers of diabetic mice via rapid tail vein injection and it resulted in high level of insulin expression. The basal hepatic insulin production mediated by hydrodynamics-based administration improved the glycemic control in type 1 diabetes dramatically and ameliorated diabetic syndromes. Hydrodynamics-based administration offers a simple and efficient way in the study of gene therapy for type 1 diabetes.
胰岛素基因的体内转移与表达是改善1型糖尿病血糖控制的一种替代策略。基于流体动力学的方法已被证明能非常有效地将裸DNA转移至小鼠肝脏。本研究通过快速尾静脉注射介导基础肝脏胰岛素生成,以确定其对1型糖尿病小鼠恢复血糖控制的影响。
将工程化胰岛素cDNA插入到巨细胞病毒(CMV)启动子下的质粒载体中,并通过流体动力学方法将其转移至链脲佐菌素诱导的糖尿病小鼠体内。检测处理后小鼠的血糖水平、体重、胰岛素水平、肝脏免疫组织学以及肝脏中胰岛素mRNA的量,以确定质粒给药后高血糖并发症的改善情况。还使用了转座子系统睡美人来延长肝脏中胰岛素的表达。
质粒给药后,糖尿病小鼠的血浆胰岛素显著增加,肝脏免疫染色呈胰岛素阳性。同时,高血糖并发症得到改善。小鼠血糖水平降至正常。处理后的糖尿病小鼠的糖耐量得到改善。体重减轻也有所缓解。快速尾静脉注射未导致任何致命结果。
我们的结果表明,胰岛素基因可通过快速尾静脉注射有效地转移至糖尿病小鼠肝脏,并导致高水平的胰岛素表达。基于流体动力学给药介导的基础肝脏胰岛素生成显著改善了1型糖尿病的血糖控制,并改善了糖尿病综合征。基于流体动力学的给药为1型糖尿病基因治疗研究提供了一种简单有效的方法。